Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer’s Drug Improves Survival in Kidney Cancer Trial

By Ryan Bushey | October 11, 2016

Roman Tiraspolsky / Shutterstock.com

Pfizer’s kidney cancer drug received mixed results over the weekend from two studies.

The company’s drug, Sutent, improved the median disease-free survival rates for patients who had localized kidney cancer that was removed via surgery, reported FiercePharma. These individuals tend to be high-risk for relapses.

Investigators running this trial, named S-TRAC, monitored patients who took a one year regimen of either Sutent or a placebo for a five-year period. The median disease-free survival rate in the Sutent group was 6.8 years while it stood at 5.6 years for the other set.

Also, this is the first positive adjuvant renal cell cancer (RCC) trial.

“For the past 10 years, Pfizer has been a leader in developing new treatments for patients with kidney cancer, and Sutent has been the most widely prescribed first-line treatment for thousands of patients with advanced RCC around the world,” said Mace Rothenberg, MD, Chief Development Officer, Oncology, Pfizer Global Product Development in a statement.

The results of S-TRAC suggest that SUTENT has the potential to extend this benefit by reducing the risk of recurrence in patients who have undergone complete surgical removal of their kidney cancer and are at high risk of cancer recurrence,” he continued.

However, Sutent didn’t fare as well in another study testing it against a rival drug called Cabometyx made by Elexlixis to treat metastatic kidney cancer, wrote Reuters.

Results from a Phase 2 study indicated Cabometyx caused a 31 percent reduction in disease progression or death when compared to Pfizer’s product. Volunteers taking Sutent experienced an increase of 5.6 months before the disease worsened while patients on a Cabometyx regimen experienced on average an 8.2 month period before their condition worsened.

Still, both companies are pleased with the results. Exelixis plans on filing a regulatory approval to sell their drug as a first-line advanced kidney cancer treatment whereas Pfizer is seeking to add another indication for Sutent to treat RCC.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50